Citi opened a “positive 90-day catalyst watch” on shares of Structure Therapeutics (GPCR) while keeping a Buy rating on the name with a $60 price target Citi views Structure’s risk/reward into the Phase 2b ACCESS and ACCESS II data for aleniglipron, expected by the end of 2025, as favorable.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Strong Market Demand and Convenience Drive Buy Rating for Structure Therapeutics
- Buy Rating for Structure Therapeutics: Aleniglipron’s Market Potential and Acquisition Appeal
- Promising Market Potential for Structure Therapeutics: Buy Rating Backed by Superior Trial Results and Market Opportunities
- Optimistic Buy Rating for Structure Therapeutics Driven by Aleniglipron’s Potential in Obesity and T2D Markets